Treace to Report Third Quarter 2023 Financial Results
16 October 2023 - 10:00PM
Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a
medical technology company driving a fundamental shift in the
surgical treatment of hallux valgus (commonly known as bunions)
through its Lapiplasty® 3D Bunion Correction® Procedure, today
announced that it will release financial results for the third
quarter of 2023 after the close of trading on Thursday, November 9,
2023. Company management will host a conference call to discuss
financial results beginning at 4:30 pm ET.
Investors interested in listening to the
conference call may do so by registering. Once registered,
participants will receive dial-in numbers and a unique pin to join
the call and ask questions. A live and archived webcast of the
event will be available on the Company’s investor relations website
at https://investors.treace.com/.
Internet Posting of
Information
Treace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The Company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical
Concepts
Treace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 65 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion Correction® System
– a combination of instruments, implants, and surgical methods
designed to surgically correct all 3 planes of the bunion deformity
and secure the unstable joint, addressing the root cause of the
bunion and helping patients get back to their active lifestyles.
Treace expanded its offering with the Adductoplasty® Midfoot
Correction System, designed for reproducible surgical correction of
the midfoot to provide further support to hallux valgus patients,
and the Hammertoe PEEK Fixation System, designed to address
hammertoe, claw toe and mallet toe deformities. For more
information, please visit www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical Concepts,
Inc.Julie Dewey, IRCChief Communications & Investor
Relations Officerjddewey@treace.com | 209-613-6945
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From Apr 2024 to May 2024
Treace Medical Concepts (NASDAQ:TMCI)
Historical Stock Chart
From May 2023 to May 2024